GC Biopharma Corp. (KRX:006280)
South Korea
· Delayed Price · Currency is KRW 150,700
+6,500 (4.51%)
Last updated: Mar 10, 2026, 11:59 AM KST
GC Biopharma Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 1,645,780 | 2,048,665 | 1,432,354 | 1,478,007 | 2,488,073 | 4,633,750 | Upgrade
|
| Market Cap Growth | 4.27% | 43.03% | -3.09% | -40.60% | -46.30% | 206.42% | Upgrade
|
| Enterprise Value | 2,790,342 | 3,129,049 | 2,368,951 | 2,204,898 | 3,075,936 | 5,228,112 | Upgrade
|
| Last Close Price | 144200.00 | 179500.00 | 124404.89 | 126814.61 | 210762.41 | 388984.60 | Upgrade
|
| PE Ratio | 29.22 | - | - | 22.58 | 20.19 | 57.17 | Upgrade
|
| Forward PE | 35.53 | 87.99 | 47.35 | 21.09 | 25.00 | 33.91 | Upgrade
|
| PS Ratio | 0.85 | 1.22 | 0.88 | 0.86 | 1.62 | 3.08 | Upgrade
|
| PB Ratio | 1.10 | 1.38 | 0.93 | 0.94 | 1.66 | 3.65 | Upgrade
|
| P/TBV Ratio | 1.91 | 1.94 | 1.34 | 1.33 | 2.31 | 4.30 | Upgrade
|
| P/FCF Ratio | 45.61 | - | - | 24.17 | 105.17 | - | Upgrade
|
| P/OCF Ratio | 17.93 | - | - | 12.40 | 19.75 | 128.81 | Upgrade
|
| PEG Ratio | - | 1.35 | 1.35 | 1.35 | 1.20 | 0.45 | Upgrade
|
| EV/Sales Ratio | 1.44 | 1.86 | 1.46 | 1.29 | 2.00 | 3.48 | Upgrade
|
| EV/EBITDA Ratio | 15.23 | 27.67 | 21.57 | 15.12 | 23.73 | 52.82 | Upgrade
|
| EV/EBIT Ratio | 29.35 | 97.66 | 69.86 | 27.32 | 41.72 | 104.18 | Upgrade
|
| EV/FCF Ratio | 77.33 | - | - | 36.05 | 130.02 | - | Upgrade
|
| Debt / Equity Ratio | 0.69 | 0.56 | 0.47 | 0.37 | 0.40 | 0.45 | Upgrade
|
| Debt / EBITDA Ratio | 7.25 | 7.32 | 6.59 | 3.95 | 4.68 | 5.72 | Upgrade
|
| Debt / FCF Ratio | 28.35 | - | - | 9.41 | 25.64 | - | Upgrade
|
| Net Debt / Equity Ratio | 0.64 | 0.54 | 0.43 | 0.30 | 0.27 | 0.25 | Upgrade
|
| Net Debt / EBITDA Ratio | 6.76 | 7.11 | 6.09 | 3.18 | 3.11 | 3.14 | Upgrade
|
| Net Debt / FCF Ratio | 26.45 | -9.41 | -7.91 | 7.57 | 17.06 | -6.63 | Upgrade
|
| Asset Turnover | 0.65 | 0.62 | 0.63 | 0.69 | 0.67 | 0.73 | Upgrade
|
| Inventory Turnover | 1.84 | 1.90 | 2.38 | 2.52 | 2.28 | 2.52 | Upgrade
|
| Quick Ratio | 0.49 | 0.55 | 0.58 | 0.96 | 1.13 | 1.15 | Upgrade
|
| Current Ratio | 1.18 | 1.56 | 1.20 | 1.81 | 1.97 | 1.92 | Upgrade
|
| Return on Equity (ROE) | 2.28% | -2.82% | -1.27% | 4.53% | 9.89% | 7.26% | Upgrade
|
| Return on Assets (ROA) | 1.11% | 0.74% | 0.82% | 2.02% | 2.00% | 1.53% | Upgrade
|
| Return on Invested Capital (ROIC) | 2.14% | 1.43% | 1.60% | 3.32% | 3.36% | 2.76% | Upgrade
|
| Return on Capital Employed (ROCE) | 2.80% | 1.60% | 1.90% | 4.10% | 3.90% | 3.20% | Upgrade
|
| Earnings Yield | 3.42% | -1.28% | -1.86% | 4.43% | 4.95% | 1.75% | Upgrade
|
| FCF Yield | 2.19% | -4.17% | -5.90% | 4.14% | 0.95% | -1.01% | Upgrade
|
| Dividend Yield | 0.99% | 0.84% | - | - | - | - | Upgrade
|
| Payout Ratio | 33.43% | - | - | 36.65% | 15.02% | 15.69% | Upgrade
|
| Total Shareholder Return | 0.99% | 0.84% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.